Sight Sciences, Inc., a Menlo Park, CA-based growth-stage medical device company focused on ophthalmology and optometry, glaucoma and dry eye disease, closed an over $30m Series E Preferred Stock financing round.
The round was led by D1 Capital Partners.
The company intends to use the funds for continued clinical and operational development and to support commercial expansion for its OMNI® and TearCare® products.
Founded in 2011 by Paul Badawi, CEO, Sight Sciences has developed, and is now commercial with products that target the underlying causes of the world’s most prevalent eye diseases. The company’s surgical glaucoma product portfolio features the OMNI® Surgical System, a dually-indicated device that facilitates the performance of both trabeculotomy and transluminal viscoelastic delivery. Using proprietary multi-modal functionality, OMNI allows surgeons to target of all three sources of resistance in the conventional outflow pathway (trabecular meshwork, Schlemm’s canal, and collector channels) with a single device and single corneal incision.
The company’s non-surgical Dry Eye product portfolio consists of TearCare® for ophthalmologists and optometrists. TearCare is a software-controlled, wearable eyelid technology that delivers highly targeted and adjustable heat to the meibomian glands of the eyelids. Leveraging the full functionality of the blinking eye, proprietary SmartLid™ technology is designed to facilitate natural meibum expression when meibum is in its softened phase.